A Phase 1/2 Single Arm Open-Label Clinical of TC-510 in Patients with Advanced Mesothelin-Expressing Cancer

Summary

Description

Sponsor

TCR2 Therapeutics

Status of enrollment

Not yet accepting new patients

Ages Eligible for Study

Adults ages 18 and up

Genders Eligible for Study

Females and Males

Disease indication

Mesothelioma, Ovarian Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer

Principal Investigator

David Oh, MD, PhD

Contact

AAhir Srinath: [email protected]

Additional study eligibility details can be found at UCSF Clinical Trials.